Clinical Trial

A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated June 25, 2024 (before its estimated October 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
As the most common subtype of lymphoma, diffuse large B-cell lymphoma (DLBCL) is an aggressive but potentially curable malignancy. However, patients with early relapse (relapse within 12 months since diagnosis or the end of first-line treatment, ER) or primary refractory had an even worse prognosis. Thus, the investigators plan to evaluate the efficacy and safety of anlotinib combined with rituximab, gemcitabine, oxaliplatin (A-RGEMOX) in the treatment of early relapsed/refractory diffuse large B-cell lymphoma.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-10-12; most recent amendment 2024-06-23.
Trial Details
NCT Number NCT06086197
Lead Sponsor Zhejiang Cancer Hospital
Conditions Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory
Enrollment 41 participants
Start Date 2023-10-01
Primary Completion 2025-10-01 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2024-06-25